Advancing Muscle-Invasive Bladder Cancer Testing and Clinical Integration

  • Explore the current treatment landscape of muscle-invasive bladder cancer
  • Examine the emerging role of ctDNA and MRD testing in bladder cancer disease monitoring and treatment selection
  • Discuss strategies for implementing novel testing approaches into clinical practice

EP. 1: Novel Neoadjuvant Therapies in MIBC

November 13th 2025

Experts discuss advancements in muscle invasive bladder cancer, focusing on innovative testing and treatment strategies to enhance patient outcomes.

EP. 2: Advancements in Perioperative Therapy for MIBC

November 13th 2025

Experts discuss the promising results of the Niagara trial, highlighting benefits of cisplatin and durvalumab for unfit patients in cancer treatment.

EP. 3: Analyzing the Role of ctDNA and Adjuvant

November 20th 2025

Experts discuss the evolving role of ctDNA in adjuvant therapy post-cystectomy, highlighting its prognostic value and implications for treatment decisions.

EP. 4: Biomarker, Diagnosis, and Evolving Treatment Paradigm in MIBC

November 20th 2025

Recent discussions highlight the significance of ctDNA in adjuvant therapy post-cystectomy, revealing its potential to predict patient outcomes and guide treatment decisions.

EP. 5: Risk Stratification and Surveillance After

December 1st 2025

Experts discuss the evolving treatment landscape for muscle-invasive bladder cancer, highlighting the shift towards perioperative approaches and the role of biomarkers.

EP. 6: Unmet Needs and the Evolving Role of MRD Monitoring in MIBC

December 1st 2025

Discover the latest insights on ctDNA testing and its impact on relapse risk in muscle-invasive bladder cancer post-surgery.